Swedish design firm Pond Healthcare Innovation has developed apps for pharmaceutical companies focusing on the European market supporting patients and clinicians. It developed a symptom tracker to support multiple sclerosis patients for Novartis and a training tool for physicians on Hyponatremia for Otsuka. Its latest collaboration with Novartis is a smart spirometer and companion app designed to evaluate lung function.
The goal of these devices is to get a regular assessment of lung function so if there is a sudden change, physicians can intervene faster and reduce the need for hospitalization.
Pond Healthcare Innovation CEO Daniel Taub said in an interview that the Air Smart spirometer device is CE-certified by European regulators and is available in Europe. Taub said that it collaborated with Novartis’s on a COPD application for the device, but he believes it could be applied to a broader variety of respiratory conditions beyond Europe.
Health Executives on Digital Transformation in Healthcare
Hear executives from Quantum Health, Surescripts, EY, Clinical Architecture and Personify Health share their views on digital transformation in healthcare.
It plans to launch a version of the smartphone-enabled device for Android users in the first quarter of 2016. The company is also working on an application to diagnose asthma.
It reflects a broader Beyond the Pill collaboration trend between pharma and digital health companies to add services and connected devices to improve patient outcomes. Cohero Health developed a smart spirometer for the U.S. market for people with respiratory problems.
Novartis did not immediately respond to a request for comment before this post was published.